Quote | Inozyme Pharma Inc. (NASDAQ:INZY)
Last: | $4.51 |
---|---|
Change Percent: | 0.87% |
Open: | $4.54 |
Close: | $4.51 |
High: | $4.63 |
Low: | $4.38 |
Volume: | 591,071 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
News | Inozyme Pharma Inc. (NASDAQ:INZY)
2024-04-09 08:00:07 ET Edward White from H.C. Wainwright issued a price target of $14.00 for INZY on 2024-04-09 06:36:00. The adjusted price target was set to $14.00. At the time of the announcement, INZY was trading at $5.87. INZY currently trades -24.97% versus its 52 ...
- Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascular pathology, visual function and patient reported outcomes (PROs) - - Natural history study highlights stroke as common feature among patients with early-onset ABCC6 Deficiency - ...
Message Board Posts | Inozyme Pharma Inc. (NASDAQ:INZY)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $INZY 22% v2,6M c5.73 f43,720M H5.95 ML.2.51 RL4.51 gapNgo | znewcar1 | investorshangout | 04/01/2023 3:27:00 AM |
Loading | INFINITI | investorshub | 02/17/2023 1:19:27 PM |
Have a feeling this about to squeeze into | Jess070283 | investorshub | 02/16/2023 3:10:59 PM |
Great week so far. Gotta keep | tj9938 | investorshub | 01/06/2023 4:00:14 PM |
Quietest board out there | tj9938 | investorshub | 12/30/2022 6:58:51 PM |
News, Short Squeeze, Breakout and More Instantly...
Inozyme Pharma Inc. Company Name:
INZY Stock Symbol:
NASDAQ Market:
Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said...
2024-04-09 08:00:07 ET Edward White from H.C. Wainwright issued a price target of $14.00 for INZY on 2024-04-09 06:36:00. The adjusted price target was set to $14.00. At the time of the announcement, INZY was trading at $5.87. INZY currently trades -24.97% versus its 52 ...
- Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascular pathology, visual function and patient reported outcomes (PROs) - - Natural history study highlights stroke as common feature among patients with early-onset ABCC6 Deficiency - ...